There is phase II support for Revlimd for mantle lymphoma. The NCCN Drugs & Biologics Compendium recognizes the use of lenalidomide for Mantle Cell lymphoma. ESMO guidelines mentions that ibutinib has a higher resposne rate but do not discount lenalidomide for salvage therapy.
Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 2009;145:344-349.
Chanan-Khan, A. A. & Cheson, B. D. (2008). Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology, 26 (9), 1544-1552.
M. Dreyling et al, Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology Issue Cover Volume 25 Issue suppl_3 September 2014
Zinzani PL, Vose JM, Czuczman MS, et al. . Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study, Ann Oncol , 2013, vol. 24 (pg. 2892-2897)